Gyros Protein Technologies


Biopharmaceutical drug development: from CMC to clinical PK


An overview of Gyrolab® immunoassays and their utility in CMC target binding assays for batch release and stability assessment. Also, for preclinical and clinical PK analysis with a view to transferring assays to a CRO.

This webinar will give an overview of a Gyrolab system and how it is used to support biopharmaceutical drug development. Uses include bioprocess application and pharmacokinetic assays. A case study from Symphogen will highlight how a Gyrolab 2-plex assay can be used to support a program for a therapeutic antibody mixture. The case study will highlight the advantages of speed, data quality and ease of transferring an assay to a CRO.

What will you learn?

  • How to maximize the performance and productivity of automated ligand-binding assays
  • How automated ligand-binding assays of two monoclonal antibodies can lead to efficient assay development and validation
  • How transferring a ligand-binding assay to a CRO can be made easier

rikke hald-1

Rikke Hald,MSc, PhD
Senior Scientist, Bioassays
Symphogen A/S (Ballerup, Denmark)

If you have problems viewing the webinar, please contact